Lacosamide, rotigotine miss Phase II endpoints

UCB (Euronext:UCB) said late Friday that top-line data showed lacosamide and rotigotine missed the primary endpoints in two separate double-blind Phase IIa trials. Lacosamide missed the primary endpoint of mean reduction of migraine rates vs. placebo in a study to prevent migraines in 218 patients. The company said reduction in headache frequency was consistently observed in all treatment groups, and it will evaluate its development plans once full analyses are available. The anticonvulsant is marketed as Vimpat for adjunctive use in the treatment of partial onset seizures in the U.S. and EU. ...